Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063141 · ClinicalTrials.gov registry record · Phase 3
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,302
- Enrollment target
NCT00063141: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00063141 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,302 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063141, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,302 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.
Interventions
- DRUG cetuximab
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,302 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00063141 record still lists
NCT00063141 is an interventional study that assigns participants to a tested intervention. Its 1,302 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 2 interventions - of which cetuximab is the first listed.
NCT00063141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00063141 about?
NCT00063141 is a clinical study titled "Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer". The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatm...
What is the current status of trial NCT00063141?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,302 participants. The study started on 2003-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00063141?
The interventions under investigation include: cetuximab (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00063141?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00063141's enrollment target sits among peer trials
1,302 188th of 2000 higher than 1,813 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
- NCT05282654 · 1,300 participants · NA
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia